Track Divis Laboratories Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -0.26 %
Low
6,530.5
High
6,744.3
1 Month returns: 2.29 %
Low
6,460.0
High
6,887.5
1 Year returns: -2.58 %
Low
5,636.5
High
7,077.7
3 Year CAGR: 23.05 %
Low
3,295.3
High
7,077.7
5 Year CAGR: 8.08 %
Low
2,730.0
High
7,077.7
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Divis Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Divis Laboratories Ltd. Shareholding Pattern
Quarterly breakdown of Divis Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Divis Laboratories Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Divis Laboratories Ltd.?
The current share price of Divis Laboratories Ltd. is ₹ 6,682.50 as of 2 Jul 2026.
What is the market capitalisation of Divis Laboratories Ltd.?
The market capitalisation of Divis Laboratories Ltd. stands at ₹ 1,77,400.00 Cr.
What is the PE ratio of Divis Laboratories Ltd.?
The Price-to-Earnings (PE) ratio of Divis Laboratories Ltd. is 69.08 as of the latest trailing twelve months data.
What is the ROE and ROCE of Divis Laboratories Ltd.?
Divis Laboratories Ltd. has a Return on Equity (ROE) of 16.19% and a Return on Capital Employed (ROCE) of 18.76% as per the latest financial reports.
What is the 52-week high and low of Divis Laboratories Ltd.?
The 52-week high of Divis Laboratories Ltd. is - and the 52-week low is -.
What is the dividend yield of Divis Laboratories Ltd.?
The dividend yield of Divis Laboratories Ltd. is 0.45% based on the current market price.
What is the FII and DII holding in Divis Laboratories Ltd.?
Foreign Institutional Investors (FII) hold 20.29%, Domestic Institutional Investors (DII) hold 18.24% and retail/public investors hold 7.41% of Divis Laboratories Ltd. shares.
What sector does Divis Laboratories Ltd. belong to?
Divis Laboratories Ltd. operates in the Healthcare sector. 48.15% of analysts have a Buy or Strong Buy rating on Divis Laboratories Ltd. with a consensus target price of ₹ 6,921.00, implying 3.57% upside from current levels.
What is the beta of Divis Laboratories Ltd.?
The beta of Divis Laboratories Ltd. is 0.59, indicating its price volatility relative to the broader market. Over the past 1 year, Divis Laboratories Ltd. has delivered an absolute return of 1.78%.
What is the RSI of Divis Laboratories Ltd.?
The 14-day Relative Strength Index (RSI) of Divis Laboratories Ltd. is 51.56, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Overview of Divis Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Divis Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Companys products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divis Laboratories Europe AG.
Divis Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Companys products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromet...
1-72/23(P)/Divis/303,, Divi Towers, Cyber Hills, Gachibowli,, HYDERABAD, 500032, India
Corporate Actions
History of Divis Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 30/share
Record date: 24th Jul 2026Ex-date: 24th Jul 2026
Announced on: 23rd May 2026
Dividend₹ 30/share
Record date: 25th Jul 2025Ex-date: 25th Jul 2025
Announced on: 17th May 2025
Dividend₹ 30/share
Record date: 2nd Aug 2024Ex-date: 2nd Aug 2024
Announced on: 25th May 2024
Dividend₹ 30/share
Record date: 11th Aug 2023Ex-date: 11th Aug 2023
Announced on: 20th May 2023
Dividend₹ 30/share
Record date: 12th Aug 2022Ex-date: 11th Aug 2022
Announced on: 23rd May 2022
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Stock Analysis
Fundamental analysis overview of Divis Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 77.0 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
77.0 / 100
High and stable ROE
The company reported strong ROE of 16.19% for 12-month ended 31 Mar 2026 and ROE improved marginally by 70 bps from 1 year ago
What is ROE (FY)?
High and stable operating margin
The company reported strong operating margin of 28.2% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 17 bps from 1 year ago
What is Operating profit margin?
Moderate EPS growth and above median growth of industry
The company delivered moderate EPS growth of 17.23% for 12-month ended 31 Mar 2026 and the growth was 9.11 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.0 as on 31 Mar 2026 and Debt to Equity remained same in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 5 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 69.08 indicates that the stock is expensive on a standalone basis and is at a 128.29% premium to industry median P/E
What is P/E Ratio?
Median: 30.26
Value 69.08
-215.443183
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -1.98% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low dividend yield
The company has a low dividend yield of 0.45%
What is Dividend yield?
Neutral
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 12.82% for 12-month ended 31 Mar 2026 and the growth was 1.58 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 11.24
Value 12.82
-82.35114662
Company's earnings are of moderate quality
Earnings quality score of 66.4 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion